This dissertation examines how haematologists make treatment decisions for elderly patients with diffuse large B-cell lymphoma (DLBCL or lymphatic cancer) and how comorbidities influence these treatment decisions. It also examines quality of life for elderly patients with DLBCL and multiple myeloma (MM or plasma cell cancer). The results reveal that comorbidities and age play a significant role in treatment decisions, such as offering treatments that aim to cure DLBCL. This dissertation also examined quality of life among DLBCL patients and found that DLBCL has a bigger impact on quality of life in younger patients than in older patients. The same is true of MM patients as well: quality of life was significantly reduced in younger patients ...
Multiple myeloma is a disease of the elderly, with about a third of patients at diagnosis older than...
To assess treatment strategies, toxicity and outcome in very elderly patients (aged >= 75 years) ...
The European Society for Medical Oncology (ESMO) consensus conference on mature B cell lymphomas and...
Elderly patients with diffuse large B-cell lymphoma (DLBCL) are frequently not treated with standard...
Abstract Elderly patients with diffuse large B-cell lympho-ma (DLBCL) are frequently not treated wit...
Background: Elderly patients with non-Hodgkin's lymphoma (NHL) are often not treated with standard i...
The means of optimally managing very elderly patients with diffuse large B-cell lymphoma (DLBCL) has...
We investigated treatment of unselected elderly patients with diffuse large B-cell lymphoma (DLBCL) ...
Introduction: Diffuse large B cell lymphoma (DLBCL) has an increasing incidence in elderly patients ...
Purpose of review The choice for an optimal treatment in older lymphoma patients is a real challenge...
Contains fulltext : 152550.pdf (publisher's version ) (Closed access
Multiple myeloma (MM) is a plasma cell neoplasm with a chronic disease course that primarily affects...
PurposeThe treatment strategy for elderly patients older than 80 years with diffuse large B-cell lym...
The treatment paradigm in older patients with malignant hemopathies is the choice between an effecti...
The objective of this study was to compare health-related quality of life (HRQOL) between diffuse la...
Multiple myeloma is a disease of the elderly, with about a third of patients at diagnosis older than...
To assess treatment strategies, toxicity and outcome in very elderly patients (aged >= 75 years) ...
The European Society for Medical Oncology (ESMO) consensus conference on mature B cell lymphomas and...
Elderly patients with diffuse large B-cell lymphoma (DLBCL) are frequently not treated with standard...
Abstract Elderly patients with diffuse large B-cell lympho-ma (DLBCL) are frequently not treated wit...
Background: Elderly patients with non-Hodgkin's lymphoma (NHL) are often not treated with standard i...
The means of optimally managing very elderly patients with diffuse large B-cell lymphoma (DLBCL) has...
We investigated treatment of unselected elderly patients with diffuse large B-cell lymphoma (DLBCL) ...
Introduction: Diffuse large B cell lymphoma (DLBCL) has an increasing incidence in elderly patients ...
Purpose of review The choice for an optimal treatment in older lymphoma patients is a real challenge...
Contains fulltext : 152550.pdf (publisher's version ) (Closed access
Multiple myeloma (MM) is a plasma cell neoplasm with a chronic disease course that primarily affects...
PurposeThe treatment strategy for elderly patients older than 80 years with diffuse large B-cell lym...
The treatment paradigm in older patients with malignant hemopathies is the choice between an effecti...
The objective of this study was to compare health-related quality of life (HRQOL) between diffuse la...
Multiple myeloma is a disease of the elderly, with about a third of patients at diagnosis older than...
To assess treatment strategies, toxicity and outcome in very elderly patients (aged >= 75 years) ...
The European Society for Medical Oncology (ESMO) consensus conference on mature B cell lymphomas and...